Sulzberger MB, Witten VH. Hydrocortisone ointment in dermatological therapy. Med Clin North Am. 1954;11:321–36. https://doi.org/10.1016/s0025-7125(16)34877-5.

Article  CAS  PubMed  Google Scholar 

Zipfel PF, Skerka C. From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term “complement.” Mol Immunol. 2022;150:90–8. https://doi.org/10.1016/j.molimm.2022.08.002.

Article  CAS  PubMed  Google Scholar 

Gooderham M. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Therapy Lett. 2013;18:1–4.

PubMed  Google Scholar 

Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. General Principles of Cell Communication. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26813/

Ding C, Song Z, Shen A, Chen T, Zhang A. Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway. Acta Pharm Sin B. 2020;10:2272–98. https://doi.org/10.1016/j.apsb.2020.03.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kano N, Ong GH, Ori D, Kawai T. Pathophysiological role of nucleic acid-sensing pattern recognition receptors in inflammatory diseases. Front Cell Infect Microbiol. 2022;12: 910654. https://doi.org/10.3389/fcimb.2022.910654.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;24(62):8973–95. https://doi.org/10.1021/acs.jmedchem.9b00444.

Article  CAS  Google Scholar 

Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022;S0190–9622(22):02256–63. https://doi.org/10.1016/j.jaad.2022.07.002.

Article  CAS  Google Scholar 

Port A, Shaw JV, Klopp-Schulze L, Bytyqi A, Vetter C, Hussey E, et al. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8. Pharmacol Res Perspect. 2021;9: e00842. https://doi.org/10.1002/prp2.842.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ClinicalTrials.gov. The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW). 2022. https://clinicaltrials.gov/ct2/show/ NCT05162586?recrs=ab&cond=enpatoran&draw=2&rank=1. Acessed 17 March 2022.

ClinicalTrials.gov. The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE). 2022. https://clinicaltrials.gov/ct2/show/ NCT05540327?recrs=ab&cond=enpatoran&draw=2&rank=2. Accessed 17 March 2022.

Szilveszter KP, Németh T, Mócsai A. Tyrosine Kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;10:1862. https://doi.org/10.3389/fimmu.2019.01862.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–87. https://doi.org/10.1111/j.1600-065X.2008.00754.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dudley AC, Thomas D, Best J, Jenkins A. The STATs in cell stress-type responses. Cell Commun Signal. 2004;2:8. https://doi.org/10.1186/1478-811X-2-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. J Am Acad Dermatol. 2017;76:736–44. https://doi.org/10.1016/j.jaad.2016.12.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin CM, Cooles FA, Isaacs JD. Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol. 2020;31(Suppl 1):100–4. https://doi.org/10.31138/mjr.31.1.100.

Article  PubMed  PubMed Central  Google Scholar 

Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of the JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15:23. https://doi.org/10.1186/s12964-017-0177-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843–62. https://doi.org/10.1038/nrd.2017.201.

Article  CAS  PubMed  Google Scholar 

Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18:545–51. https://doi.org/10.1016/j.tcb.2008.08.008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022;14:1001. https://doi.org/10.3390/pharmaceutics14051001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, Nicolaidou E, Stratigos A, Rigopoulos D, et al. The JAK/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review. J Clin Med. 2022;11:4431. https://doi.org/10.3390/jcm11154431.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148:927–40. https://doi.org/10.1016/j.jaci.2021.08.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein B, Treudler R, Simon JC. JAK inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results, and potential adverse effects. J Dtsch Dermatol Ges. 2022;20:19–24. https://doi.org/10.1111/ddg.14668.

Article  PubMed  Google Scholar 

Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in Dermatology. Front Immunol. 2019;10:2847. https://doi.org/10.3389/fimmu.2019.02847.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kerkemeyer KLS, Sinclair RD, Bhoyrul B. Topical tofacitinib for the treatment of alopecia areata affecting facial hair. Br J Dermatol. 2021;185:677–9. https://doi.org/10.1111/bjd.20419.

Article  CAS  PubMed  Google Scholar 

Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol. 2018;78:1207–9. https://doi.org/10.1016/j.jaad.2018.02.031.

Article  PubMed  Google Scholar 

Qiu Q, Feng Q, Tan X, Guo M. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Pharmacol. 2019;12:547–54. https://doi.org/10.1080/17512433.2019.1615443.

Article  CAS  PubMed  Google Scholar 

Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol. 2022;S0190–9622(22):02989–99. https://doi.org/10.1016/j.jaad.2022.11.005.

Article  CAS  Google Scholar 

King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85:379–87. https://doi.org/10.1016/j.jaad.2021.03.050.

Article  CAS  PubMed  Google Scholar 

Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, et al. Selectivity profile of the Tyrosine Kinase 2 inhibitor deucravacitinib compared with Janus Kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021;11:1763–76. https://doi.org/10.1007/s13555-021-00596-8.

Article  PubMed  Google Scholar 

Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402. https://doi.org/10.1038/s41392-021-00791-1.

Article  PubMed  PubMed Central  Google Scholar 

Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, et al. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022;12:7140. https://doi.org/10.1038/s41598-022-10777-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li N, Gou ZP, Du SQ, Zhu XH, Lin H, Liang XF, et al. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clin Rheumatol. 2022;41:677–88. https://doi.org/10.1007/s10067-021-06003-z.

Article  PubMed  Google Scholar 

Elmariah SB, Smith JS, Merola JF. JAK in the [Black] Box: A Dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol. 2022;23:427–31. https://doi.org/10.1007/s40257-022-00701-3.

Article  PubMed  Google Scholar 

Rous PA. sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med. 1911;13:397–411. https://doi.org/10.1084/jem.13.4.397.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Czernilofsky AP, Levinson AD, Varmus HE, Bishop JM, Tischer E, Goodman HM. Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for the gene product. Nature. 1980;287:198–203. https://doi.org/10.1038/287198a0.

Article  CAS  PubMed  Google Scholar 

Parker RC, Varmus HE, Bishop JM. Expression of v-src and chicken c-src in rat cells demonstrates q